Kaplan-Meier curves for time to first dose of anti-TNF therapy
4.7
$ 9.00
In stock
(232)
Product Description
Adalimumab in patients with vision-threatening uveitis: real-world
Adalimumab plus Methotrexate for Uveitis in Juvenile Idiopathic
Real-world clinical effectiveness and safety of vedolizumab and
Relapse rate following withdrawal of anti-TNF therapy in patients
Comparison of drug survival between infliximab and adalimumab in
Vedolizumab has longer persistence than infliximab as a first-line
Effectiveness and Safety of the Sequential Use of a Second and
Vedolizumab has longer persistence than infliximab as a first-line
Predictive factors of clinical response to treatment with anti-TNF
First-Line Biologics for Psoriatic Arthritis: Have Patient
POS0657 SURVIVAL OF BARICITINIB VS ANTI-TNF AS THE FIRST
Calf Intestinal Alkaline Phosphatase, a Novel Therapeutic Drug for
/cdn.vox-cdn.com/uploads/chorus_image/image/72369744/1174660036.0.jpg)
